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Abstract
This study assessed agreement between radiation oncologist- and cancer patient-reported
perceptions about cancer diagnosis, time since diagnosis, treatment purpose, and whether
life expectancy had been discussed; and described preferences for prognosis discussions.
Adult cancer patients receiving radiotherapy at a Japanese hospital were invited to complete
a touchscreen tablet survey. Patient survey responses were linked and comparisons made
with a survey completed by their radiation oncologist. Among 146 cancer patient-oncologist
dyads, there was almost perfect agreement on cancer diagnosis (ĸ = 0.88, 95% CI: 0.82–
0.94), substantial agreement on time since diagnosis (ĸ = 0.70, 95% CI: 0.57–0.83) and
moderate agreement on whether treatment goal was curative or palliative (ĸ = 0.44, 95% CI:
0.28–0.57; all p’s < 0.0001). Agreement about whether a life expectancy discussion had
occurred was less than expected by chance (κ = -0.06, p = 0.9). Radiation oncologists
reported that they had spoken to over two thirds of patients about this, whilst less than one
third of patients stated that this discussion had occurred with their radiation oncologist. Over
half of the patients who had not discussed life expectancy wanted to. Patients had variable
preferences for whether they (80%), their radiation oncologist (78%) or their partner/family
(52%) should decide whether they discuss their life expectancy. Although patient self-
reported information about diagnosis and time since diagnosis appears to be reasonably
accurate (compared with clinician-reported information), limitations of self-reported data
about prognostic discussions were highlighted by poor agreement between patient- and
clinician-reported information about whether prognostic discussions have occurred. Addi-
tional support is needed to improve prognosis communication and understanding in radia-
tion oncology settings.
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Introduction
Cancer is a leading cause of death and morbidity worldwide [1]. For patients, having an
accurate understanding of their diagnosis, prognosis and goals of treatment can facilitate
informed treatment decision making [2] and can influence important patient-centred
outcomes such as reduction in aggressive end-of-life medical care and improvements
in quality of life [3, 4]. The provision of information about diagnosis and prognosis is
important to most cancer patients in Western countries [5, 6], and oncologist communica-
tion of this key information is increasingly considered to be part of standardised cancer
care [7, 8]. However, patient misunderstanding of their illness may vary due to limited edu-
cation, denial, poor interpersonal communication [9, 10], or as a result of family and health
professional information "gate keeping" [10–12]. Few studies have examined agreement
between oncologist-reports and cancer patients’ understanding of their diagnosis [13],
purpose of treatment [14], preferences for and perceptions of life expectancy discussions
[15–17].
Cancer patients’ preferences for prognostic information are complex, and may vary
across individuals and cultures. While up to 81% of cancer patients in Western countries
want to discuss their life expectancy [5, 6], it has been reported that a smaller proportion
of patients in Japan want this information [18]. Western guidelines recommend a patient-
centred approach that is responsive to individual preferences for if, when and how much
information about prognosis is discussed [19–21]. A more paternalistic approach to diagno-
sis and prognosis disclosure, where their doctor and/or family decides if and how much
patients are told, may be more common in non-Western cultures [22–24]. Recent research
with Chinese cancer patients and Australian Asian migrants suggests that this disclosure
method may be more reflective of family and clinician preferences, rather than the prefer-
ences of patients [25, 26]. A study with 201 patients and 40 physicians in Japan more than
two decades ago identified that clinicians typically underestimated the level of information
that patients wanted [13].
Radiotherapy is a major treatment modality for cancer [27], with utilisation rates of
between 48–52% recommended in Western settings [27]. Rates of utilisation have been
increasing in Japan over the past two decades, from approximately 15% of all newly diag-
nosed cancer cases being treated in 1990, to approximately 28% during in 2009 [28]. Reports
from Western settings indicate that it could be expected that the purpose of radiotherapy
treatment be curative for 78–84% and palliative for 16–22% of cancer cases treated with
radiotherapy [29]. Despite patient life expectancy often being overestimated by radiation
oncologists [30, 31], it is reasonable to expect that treatment goals would have been discussed
with patients when seeking informed consent for radiotherapy [2, 19]. Research into cancer
patients’ prognosis disclosure experiences has largely focused on patients diagnosed with
advanced cancer or specific tumour types [32–35]. This study addresses a need to explore
prognosis disclosure experiences and understanding among a heterogeneous sample of
early- and advanced-stage cancer patients with a range of diagnoses and prognoses [36]. The
objectives of this study were to: Assess agreement between radiation oncologist- and patient-
reported information about the patient’s cancer diagnosis, time since diagnosis, purpose of
treatment, whether prognosis (life expectancy) had been discussed; describe the proportion
of cancer patients who have not discussed life expectancy with their radiation oncologist,
but want to; and describe radiation oncologists’ and patients’ views about who should decide
whether life expectancy is discussed.
Agreement between patients’ and radiation oncologists’ cancer diagnosis and prognosis perceptions
PLOS ONE | https://doi.org/10.1371/journal.pone.0198437 June 8, 2018 2 / 14
Funding: This work was supported by Dr Lisa
Mackenzie’s 2011 Prime Ministers’ Australia Asia
Endeavour Award [2485_2011]. A/Prof Mariko
Carey is supported by an Australian National Health
and Medical Research Council Translating
Research into Practice (TRIP) Fellowship
[APP1073031]. Dr Lisa Mackenzie is supported by
a Postdoctoral Fellowship grant [PF-16-011] from
the Australian National Breast Cancer Foundation.
This work was also supported by a Behavioural
Science Strategic Research Partnership Grant
(CSR11-02) from Cancer Council NSW to the
Newcastle Cancer Control Collaborative, and
infrastructure funding from the Hunter Medical
Research Institute. The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Materials and methods
Ethics approvals
Approvals were obtained from the University of Newcastle Human Research Ethics Commit-
tee (reference H-2011-0310) and Kyoto University Hospital Institutional Review Board (refer-
ence E1324), and investigations were conducted according to the principles expressed in the
Declaration of Helsinki.
Study design
Cross-sectional survey of patients and radiation oncologists.
Sample and setting
Participants were recruited from a radiotherapy (RT) department in a large University hospital
in Japan between April and July 2012. Patients who were aged 20 years or more, receiving
external beam radiotherapy for cancer, and were physically and mentally able to participate
were eligible for the study. Patients who were unable to provide informed consent and com-
plete the survey in Japanese were excluded, as were those with less than two weeks of their
treatment course within the study period (to ensure adequate time for eligibility screening,
introductions and recruitment).
Procedure
Nursing staff assessed patients attending the RT treatment centre for eligibility, and provided
them with a study summary flyer. Nursing staff introduced interested patients to the study
research assistant (RA) who explained the study and sought informed consent. Patients who
provided written informed consent to having their survey responses compared to their radia-
tion oncologists’ survey responses were asked to write their name and date of birth on a paper
slip alongside their unique study identification number. At the conclusion of each recruitment
day, this form was attached to a radiation oncologist survey with the corresponding number
by the RA and distributed to the relevant radiation oncologist/s. All participating radiation
oncologists provided written informed consent.
Measures
Patient questionnaire. The patient survey was administered via Acer Iconia Tab A500
using the Rollapoll application (CREOSO Corp, Phoenix, Arizona). Awareness of a cancer
diagnosis was assessed with the question "Do you know your diagnosis?". Participants who
knew their diagnosis were asked their primary cancer diagnosis (response options: "Breast";
"Colorectal"; "Prostate"; "Lung"; "Melanoma"; "Don’t know" and "Other (please specify)", diag-
nosis month and year, and “What do you understand to be the main aim of your current treat-
ment?” (response options: "To cure the cancer"; "To prevent the cancer from coming back";
"To control symptoms of cancer [cure is not possible]"). Participants who were aware of their
diagnosis were asked to indicate whether they were willing to answer survey questions about
life expectancy [37]. Participants willing to complete this section were asked "Have you and
your radiation oncologist talked about your life expectancy?" Those who answered "yes" to the
previous question were asked single-choice closed-ended questions, including "How did the
discussion about life expectancy begin?" (response options: “I asked my doctor if we could talk
about it”; “My doctor asked me if I wanted to talk about it”; “My doctor discussed it without
asking me first”; “Other”); and "While my radiation oncologist cannot be certain, he/she has
suggested that currently. . ." (response options: “My cancer diagnosis will not affect my life
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expectancy”; “It is far too early to tell”; “I will live more than 5 years”; “I will live for 2–5 years”;
“I will live for less than 2 years”). Respondents who indicated that they had not talked to their
radiation oncologist about their life expectancy were asked "Would you like to talk to your
doctor about your life expectancy?" (response options: “Yes”; “No”). Participants also indicated
their level of agreement with five non-mutually exclusive statements relating to their prefer-
ences for who should decide whether they discuss life expectancy with their radiation oncolo-
gist. Questions and response options (see S1 File) were based on those used by Mackenzie et al
[36].
Radiation oncologist questionnaire. A paper survey provided to radiation oncologists
(see S2 and S3 Files for the English and Japanese versions, respectively) asked similar questions
about patients’ disease characteristics, purpose of treatment, and life expectancy discussions.
Statistical analysis
Patient and radiation oncologist surveys were matched by a unique identification code, and
agreement was assessed by comparing patients’ and radiation oncologists’ responses to equiva-
lent questions. If a radiation oncologist or patient response was missing, the pair was excluded
from analysis for that item. Patient- and radiation oncologist-reported cancer diagnoses were
recoded into the following diagnostic groups: breast, prostate, lung, oesophageal, head and
neck, other, don’t know, or patient not aware of cancer diagnosis. If a patient or radiation
oncologist reported a diagnosis of "other" cancer types, responses were checked by a breast
cancer surgeon (ES) to ensure consistent English translation. Days since diagnosis was calcu-
lated based on participants’ survey completion date (using the 15th of the month to approxi-
mate diagnosis dates), and then categorised as: i. < = 90 days; ii.>90 to< = 180 days; iii.
>180 to< = 365 days; and iv. >365 days. Observed agreement and Cohen’s κ or bias adjusted
weighted κ with 95% CIs (estimated using bootstrapping with 1000 repetitions) are reported.
Extent of agreement was assessed using Cohen’s kappa estimates (qualitatively classified as:
<0 = less than chance agreement; 0.01–0.20 = slight agreement; 0.21–0.40 = fair agreement;
0.41–0.60 = moderate agreement; 0.61–0.80 = substantial agreement; 0.81–0.99 = almost per-
fect agreement) [38]. P-values are reported for the hypothesis tests that kappa = 0 (i.e. agree-
ment is not greater than chance), and a significance level of 5% used.
The percentage of patients who had not discussed their life expectancy with their radiation
oncologists but wanted to was also estimated with 95% Confidence Intervals (CIs). The per-
centage of patients and radiation oncologists agreeing or strongly agreeing that life expectancy
disclosure should be (non-mutually exclusively) patient-determined, partner/family deter-
mined, and clinician-determined was estimated with 95% CIs. Life expectancy disclosure
responses mapped to these categories are described in S1 Table. Data analyses were conducted
using Stata version 11.2 (Statacorp LP, College Station, TX) software.
Sample size
An overall sample of 150 patients (with a 70% response rate to the optional life expectancy sec-
tion) would allow prevalence estimates with 95% CIs within ±15% of the point estimate for
kappa of 0.5 or higher (assuming proportions of 50%).
Results
Consent rates—Patient and radiation oncologist survey
Of 262 eligible patients, 152 completed surveys were eligible for inclusion in the analysis (com-
pletion rate 58%) [39]. Of the patients with completed surveys, 151 also gave consent to have
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their responses compared to their radiation oncologist’s. A total of 16 radiation oncologists
participated in the study. Four radiation oncologist surveys were missing the unique ID num-
ber required for data linkage, and one radiation oncologist survey was not returned to the
research team. This left a total of 146 patient-radiation oncologist survey pairs available for
analysis. Fifty-five percent of patient respondents were male. Patients were a median of 64
years of age (Q1: 58, Q3: 72) and had a median of 12 years of education (Q1: 12, Q3: 16).
The majority of patients (n = 120; 82%) reported that they lived with their husband, wife or
partner.
Agreement between patients and radiation oncologists about cancer
diagnosis and treatment purpose
Table 1 presents data on patients’ cancer diagnosis categories, based on patient and radiation
oncologist survey responses. All 141 (97%) patients who were aware of their diagnosis reported
that they were informed of this by a doctor (not by family or others). There was 90% observed
agreement between patient- and radiation oncologist-reported cancer diagnosis category, with
a Cohen’s ĸ of 0.88 (95% CI: 0.82, 0.94, p< 0.0001) indicating almost perfect agreement. Of
the 14 cases where there was disagreement between patient- and radiation oncologist-reported
cancer type, five patients indicated that they were unaware they were diagnosed with cancer,
and another five that they did not know what their cancer type was.
Table 2 shows the numbers of patients and radiation oncologists who reported length of
time since the patient’s cancer diagnosis within each category, and provides an indication of
agreement between these two sources. Observed agreement between patients and radiation
oncologists regarding the approximate number of months since cancer diagnosis was 91%,
and a weighted ĸ of 0.70 (95% CI: 0.57, 0.83, p< 0.0001) indicating that agreement was
Table 1. Patient-reported and radiation oncologist-reported cancer diagnosis (n = 146).
Prevalence (by data source)
Cancer diagnosis Patient report Radiation oncologist report
n (%) n (%)
Breast 37 (25%) 38 (26%)
Prostate 37 (25%) 37 (25%)
Lung 14 (9.6%) 15 (10%)
Oesophageal 12 (8.2%) 11 (7.5%)
Head & Neck a 10 (6.8%) 15 (10.2%)
Other b 26 (18%) 30 (21%)
Don’t know 5 (3.4%) 0 (0%)
Not aware of cancer diagnosis 5 (3.4%) N/A (0%)
a. “Head & Neck Cancer” category includes the following responses: head and neck cancer, pharyngeal cancer,
hypopharyngeal cancer, oropharyngeal cancer, nasal cavity cancer, nasopharynx cancer, paranasal cavity cancer, oral
cavity cancer, maxillary sinus cancer, laryngeal cancer, tongue cancer, ethmoid sinus cancer, right maxillary gingival
cancer
b. “Other Cancer” category includes the following responses: kidney cancer, cholangiocarcinoma, pituitary tumor,
pancreatic cancer, malignant lymphoma, sarcoma, brain tumor, benign meningioma, ascending colon cancer liver
metastasis, sacro-iliac bone cancer, ovarian cancer, mesothelioma, tumor, cervical cancer, follicular lymphoma,
gastric cancer, optic nerve meningioma or optic lymphoma, endometrial cancer, merkel cell cancer, anal canal
cancer, intrahepatic bile duct cancer, liver cancer, malignant pleural mesothelioma, meningioma, pituitary adenoma,
pleural mesothelioma, skin cancer, urachal cancer
https://doi.org/10.1371/journal.pone.0198437.t001
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substantial. There was greater than 12 months discrepancy between patient- and radiation
oncologist-reported time since diagnosis for 17 survey pairs. The maximum discrepancy was
151 months.
Table 3 shows the number and percentage of patients who agreed and disagreed with
their radiation oncologist regarding the purpose of treatment. Observed agreement between
patients and radiation oncologists regarding the aim of treatment was 72%, with a Cohen’s ĸ of
0.44 (95% CI: 0.28, 0.57, p< 0.0001) indicating moderate agreement.
Agreement between patients’ and radiation oncologists’ about whether life
expectancy was discussed
Of 146 completed radiation oncologist surveys, radiation oncologists indicated that they had
spoken to 67% of patients (n = 98) about how cancer might influence their life expectancy.
Radiation oncologist responses indicated that cancer was not likely to affect the life expectancy
of 14% of patients (n = 21), while 42% (n = 62) were expected to live for more than five years;
22% (n = 32) for 2–5 years and 21% (n = 31) less than two years.
Of the 141 patient respondents who indicated that they were aware of their cancer diagno-
sis, 82% (n = 116, 95% CI: 75%, 88%) were willing to answer questions about their life expec-
tancy. Both patient and radiation oncologist responses to the question about whether a life
expectancy discussion had occurred were available for 113 survey pairs. Table 4 shows the per-
centage of patients and radiation oncologists reporting that life expectancy had been discussed.
Table 2. Number and percentage of patients who agreed with radiation oncologists on approximate length of time since cancer diagnosis (n = 137).
Radiation oncologist report
Patient report 90 days or less 91–180 days 181–365 days 365 days or more TOTAL
90 days or less 31 (79%) 0 (0%) 3 (7.7%) 5 (14%) 39
91–180 days 3 (7.7%) 21 (91%) 3 (7.7%) 2 (5.6%) 29
181–365 days 3 (7.7%) 2 (8.7%) 28 (72%) 1 (2.8%) 34
365 days or more 2 (5.1%) 0 (0%) 5 (13%) 28 (78%) 35
TOTAL 39 23 39 36 137
https://doi.org/10.1371/journal.pone.0198437.t002
Table 3. Number and percentage of patients who agreed with their radiation oncologists about the aim of current cancer treatment (n = 138).
Radiation oncologist report
Patient report To cure the cancer To prevent the cancer coming back To control symptoms (cure not possible) TOTAL
To cure the cancer 73 (86%) 12 (36%) 12 (60%) 97
To prevent the cancer coming back 9 (11%) 21 (64%) 3 (15%) 33
To control symptoms (cure not possible) 3 (3.5%) 0 (0%) 5 (25%) 8
TOTAL 85 33 20 138
https://doi.org/10.1371/journal.pone.0198437.t003
Table 4. Number and percentage of patients reporting life expectancy disclosure experiences that agreed with
their radiation oncologist (n = 113).
Radiation oncologist perceived disclosure
Patient perceived disclosure Yes No TOTAL
Yes 11 (14%) 8 (24%) 19
No 68 (86%) 26 (76%) 94
TOTAL 79 34 113
https://doi.org/10.1371/journal.pone.0198437.t004
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Radiation oncologists reported that they had spoken to 79 patients (70%, 95% CI: 61–78%)
about how cancer might influence their life expectancy. However, only 19 patients (17%, 95%
CI: 10–25%) reported that they had discussed life expectancy with their radiation oncologist,
and only seven could provide a specific life expectancy estimate. Over half (58%; 95% CI: 46–
68%) of patients who reported that they had not discussed life expectancy wanted to. There
was 33% observed agreement between patients and radiation oncologists on whether life
expectancy had been discussed, with Cohen’s κ = -0.06 (95% CI: -0.17, 0.05, p = 0.89) indicat-
ing that agreement was less than what would have been expected by chance.
Perceptions about who should decide whether life expectancy is discussed
Fig 1 shows the proportion of patients and radiation oncologists who agreed or strongly agreed
to items indicating that the patient, radiation oncologist, and partner/family should decide
when life expectancy information is disclosed. Patients had mixed preferences for the patient,
radiation oncologist and partner/family to decide whether life expectancy is discussed. The
majority of radiation oncologists agreed that the patient should decide whether they discuss
how cancer may influence their life expectancy.
Discussion
Few studies examine the concordance between radiation oncologists’ and cancer patients’ per-
ceptions of key information related to the diagnosis: cancer type,[13] aims of treatment,[14]
preferences for and perceptions of life expectancy discussions [15–17, 40, 41]. As such, this
study provides guidance on areas of strengths and weaknesses in doctor-patient communica-
tion about these topics.
Agreement between cancer patients and their radiation oncologist regarding type of cancer
diagnosis and months since diagnosis was found to be substantial to almost perfect. In 1992 an
estimated 18% of cancer patients in Japan were informed of their diagnosis (based on reports
of bereaved family carers),[42] while in our 2012 study 88% of patients were able to accurately
report their diagnosis. Increased rates of cancer diagnosis awareness may reflect changes in
Fig 1. Percentage (and 95% CIs) of patients and radiation oncologists who agreed or strongly agreed with each (non-mutually
exclusive) life expectancy disclosure approach preference.
https://doi.org/10.1371/journal.pone.0198437.g001
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hospital policies, increased emphasis on patient autonomy and patient centred care, and
increased availability of communication skills training programs for cancer clinicians [43].
The radiation oncologist sample reported similar proportions of patients received treat-
ment with palliative intent (14%) to what we would expect based on reports from Western set-
tings (16–22%) [29]. However, sixty percent of patients whose radiation oncologist indicated
they were treating with a palliative aim (i.e. reported the treatment aim was “to control symp-
toms [cure not possible]) believed they were being treated curatively. Agreement between
patients and radiation oncologists on treatment aim ranged from fair to moderate, suggesting
that patients understand less about their prognosis than about their diagnosis. This compara-
tively low agreement between patients and radiation oncologists may be due to physician fac-
tors such as inability to convey information about this issue in a way which is understandable
to the patient [44] or concerns about the lack of adequate psychosocial support to help patients
cope with knowledge of a poor prognosis [10]. There may also be patient factors at play, such
as denial [2, 44].
The aforementioned finding that 60% of patients reported an overly optimistic treatment
goal may be a result of their not having an accurate understanding of their life expectancy [10],
with the majority of patients (83%) reporting that they had not discussed life expectancy with
their radiation oncologist. This figure is higher than the 47% of radiotherapy patients who
reported that they had not discussed life expectancy with their clinician in a recent Australian
study [36], suggesting potential cultural or health care differences. An underlying cultural fac-
tor that may be influencing high rates of patient-reported non-disclosure of life expectancy
estimates is physicians often having to navigate disclosure interactions within traditional fam-
ily-centric consultation models [45, 46] whether or not there is concordance between patient
and family disclosure preference on if and how this is done [35, 47]. Additionally, Japanese
cultural norms of maintaining harmony and respect may lead to patient hesitation in asking
questions and expressing information preferences within patient-physician interactions [45,
48].
Of the participants who reported they had not discussed life expectancy, 58% indicated that
they wished to, consistent with the Japan-based work of Fujimori and colleagues reporting
50% of people with cancer would like to be told their life expectancy if they were to receive bad
news [18]. Similar within-culture variation in individual patients’ preferences for disclosure of
life expectancy information has been reported in Western settings [36, 49]. Taken together
with the finding that radiation oncologists were able to provide a life expectancy estimate
for all 146 patients (whilst only 19 patients indicated they had discussed this and only seven
patients were able to report such an estimate), this unmet need suggests a requirement to bet-
ter elicit and respond to patients’ preferences for life expectancy information in this setting.
There are likely to be common factors across Western and non-Western settings that contrib-
ute patient-reported non-disclosure of life expectancy information, including time pressure
within the oncology consultation [50], physician discomfort with discussing life expectancy
[32, 51], as well as patient health literacy and recall of information [32]. Given that Japanese
patients may be unlikely to ask questions or directly express their information preferences dur-
ing medical consultations, physicians’ use of open-ended questions about information prefer-
ences may bring about improved patient satisfaction with cancer care communication [52].
Our finding of poor agreement between clinicians and patients regarding life expectancy
disclosure and aims of treatment must be understood in the context of patient and clinician
views about how such discussions should be initiated. Our data indicated substantial differ-
ences between clinician and patient views regarding who should determine whether a life
expectancy discussion takes place. Radiation oncologists agreed that the patient should decide
(96%); while a much smaller percentage agreed that the doctor should decide (21%); and the
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family should decide (24%) whether life expectancy is discussed. In contrast, 80% of patients
indicated that they should decide themselves; 78% that the radiation oncologist should decide;
and 52% that the family should decide whether life expectancy should be discussed. A survey
of the general population in Japan (aged between 40–60 years) identified similar overlapping
preferences for self, clinician and family directed disclosure of life expectancy information
[53]. These complex patient preferences for shared decision-making have been previously
reported in international settings [54, 55], and appear to be consistent with what might be
expected in consensus-based family-centric medical communication and decision-making
models in Japanese settings [56]. Our findings suggest that while radiation oncologists may be
waiting for patients to take the initiative in raising the issue of life expectancy during treatment
(either with them or another clinician responsible for cancer treatment);[44] patients may be
expecting clinicians to take a more active role in starting the discussion prior to and during RT
[57]. This may account, in part, for discrepancies between patient- and radiation oncologist-
reported life expectancy disclosure experiences.
It is possible that generalisability of the current results to patients receiving radiotherapy
may be limited due to recruitment from a single university hospital, and the opt-out life expec-
tancy section (with no electronic response validation applied to allow respondents to easily
skip questions within this section) which produced a smaller sample (82%) and some missing
data. A limitation is that although we included a broad range of cancer types, our sample was
not sufficient to enable us to explore whether there were significant differences between the
experiences of people with different types of cancer. Radiation oncologist surveys were not
identifiable, and we were not able to assess radiation oncologists’ sociodemographic or train-
ing characteristics or variations in preferences for disclosure and other outcomes. Addition-
ally, we did not assess whether physicians had disclosed life expectancy information to family
members. This study did not assess whether patients had discussed their life expectancy with
another healthcare provider involved in their cancer care, with the study focus instead being
on assessing whether treating radiation oncologists discuss radiotherapy treatment goals with
patients when seeking informed consent for the treatment [2, 19]. Although this study was
limited to patient and radiation oncologist self-reported life expectancy disclosure experience
(rather than being supplemented with more objective measures such as audiotaped consulta-
tions), this allowed us to assess patients’ understanding taken from consultations.
Research and practice implications
These findings should be reassuring for researchers in cancer treatment settings relying on
patient self-reported information about diagnosis and time since diagnosis, with high agree-
ments rates suggesting reasonable accuracy. However, differing views between patients and
radiation oncologists about the purpose of treatment and whether a life expectancy discussion
had occurred highlights the limitations of both patient- and clinician-reported information
about whether prognostic discussions have occurred and what was communicated.
Given that many patients had not discussed life expectancy but wanted to, there is a need to
address how these discussions are initiated in clinical practice. In Western settings, a patient-
centred approach is recommended (i.e. the doctor should ask the patient if they want to discuss
life expectancy). However, our findings also support past research that indicated that not all
patients want to be responsible for (or involved in) negotiation with their clinician regarding
life expectancy disclosure. Given that family-centric medical interactions and decision-making
is common in Japan, there is a need to explore how to accommodate overlapping preferences
for doctor-, family- and patient-determined prognosis disclosure approaches. Patient educa-
tion and strategies such as patient question prompt lists may assist patients in understanding
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that they have right to initiate discussions regarding life expectancy, and equip them with the
necessary skills to do this [58]. However, studies have also shown that question prompt lists
are most effective when endorsed by the clinician,[59] therefore, it is important to target the
communication skills of the both patients and clinicians [60]. Japanese models of communica-
tion skills training for oncology specialists (e.g. the ‘SHARE’ staged model for breaking bad
news to cancer patients in a preference sensitive way [61]), have had a limited focus on radia-
tion oncologists [62]. There is a need for further research assessing and addressing radiation
oncologists’ skills in negotiating patients’ preferences for the timing, content and approach to
life expectancy disclosure [60, 62].
Conclusion
High levels of agreement between patients and clinicians regarding type and time since diag-
nosis supports the reliability of patient-reported disease information in survey research. Poor
agreement between patients’ and radiation oncologists’ perceptions of life expectancy discus-
sions suggests a need for improved patient-clinician communication. There is a need to
explore how to accommodate overlapping patient preferences for doctor-, family- and patient-
determined prognosis disclosure in Japan.
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